Management of pain in chronic kidney disease

Progress in Palliative Care

Volumn 17, Issue 4, 2009, Pages 186-195

  Davison, Sara N ^a,c   Ferro, Charles J ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

End of life care; End stage renal disease; Opioids; Pain; Palliative care

Indexed keywords

ALFENTANIL; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BUPRENORPHINE; CANNABIDIOL; CANNABINOID; CANNABIS; CAPSAICIN; CARBAMAZEPINE; CLONAZEPAM; CODEINE; DESIPRAMINE; FENTANYL; GABAPENTIN; HYDROMORPHONE; METHADONE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PETHIDINE; PREGABALIN; TETRAHYDROCANNABINOL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ANOREXIA; ATAXIA; BEDTIME DOSAGE; BLURRED VISION; BRIEF PAIN INVENTORY; CARDIOTOXICITY; CHRONIC KIDNEY DISEASE; CHRONIC PAIN; CONFUSION; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DISTRESS SYNDROME; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; FATIGUE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART MUSCLE CONDUCTION DISTURBANCE; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; INTRACTABLE PAIN; LIBIDO DISORDER; LIVER TOXICITY; MCGILL PAIN QUESTIONNAIRE; NAUSEA; NEUROPATHIC PAIN; OPIATE ADDICTION; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PERITONEAL DIALYSIS; PRURITUS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SODIUM RETENTION; STOMACH IRRITATION; TACHYCARDIA; TREMOR; URINE RETENTION; VISCERAL PAIN; VISUAL ANALOG SCALE; VISUAL DISORDER; VOMITING; WEAKNESS; WEIGHT GAIN; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

EID: 70350148546     PISSN: 09699260     EISSN: 1743291X     Source Type: Journal    
DOI: 10.1179/096992609X12455871937189     Document Type: Review

References (106)

1. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis 2003; 42: 1239-1247.
2. Weisbord SD, Fried LF, Arnold RM et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol 2005; 16: 2487-2494.
3. Murphy EL, Murtagh FE, Carey I, Sheerin NS. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool. Nephron Clin Pract 2008; 111: c74-c80.
4. Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int 2006; 69: 1621-1625.
5. Saini T, Murtagh FE, Dupont PJ, McKinnon PM, Hatfield P, Saunders Y. Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease. Palliat Med 2006; 20: 631-636.
6. Weisbord SD, Fried LF, Mor MK et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2007; 2: 960-967.
7. Bailie GR, Mason NA, Bragg-Gresham JL, Gillespie BW, Young EW. Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription. Kidney Int 2004; 65: 2419-2425.
8. Davison SN. Chronic kidney disease: psychosocial impact of chronic pain. Geriatrics 2007; 62: 17-23.
9. Kimmel PL, Emont SL, Newmann JM, Danko H, Moss AH. ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis 2003; 42: 713-721.
10. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in endstage renal disease patients. Am J Kidney Dis 2001; 38: 443-464.
11. Patel SS, Shah VS, Peterson RA, Kimmel PL. Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. Am J Kidney Dis 2002; 40: 1013-1022.
12. Davison SN, Jhangri GS. The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients. J Pain Symptom Manage 2005; 30: 465-473.
13. Davison SN, Jhangri GS, Johnson JA. Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 3189-3195.
14. World Health Organization. Cancer Pain Relief: With a guide to opioid availability, 2nd edn. Geneva: WHO, 1996.
15. Binik YM, Baker AG, Devins GM, Guttmann RD. Pain, control over treatment, and compliance in dialysis and transplant patients. Kidney Int 1982; 21: 840-848.
16. Parfrey PS, Vavasour HM, Bullock HM, Gault MH. Clinical features and severity of non specific symptoms in dialysis patients. Nephron 1988; 50: 121-128.
17. Anderson KO, Mendoza TR, Valero V et al. Minority cancer patients and their providers: Pain management attitudes and practice. Cancer 2000; 88: 1929-1938.
18. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-299.
19. Daut RL, Cleeland ES, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 197-210.
20. Weisbord SD, Fried LF, Arnold RM et al. Development of a symptom assessment instrument for chronic hemodialysis patients: the Dialysis Symptom Index. J Pain Symptom Manage 2004; 27: 226-240.
21. Barakzoy AS, Moss AH. Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol 2006; 17: 3198-3203.
22. Chambers EJ, Germain M, Brown E. (eds) Supportive Care for the Renal Patient. Oxford: Oxford University Press, 2004.
23. Aronoff GR, Berns JS, Brier M et al. Drug Prescribing in Renal Failure, 4th edn. Philadelphia, PA: American College of Physicians, 1998.
24. Ashley C, Bunn R. The Renal Drug Handbook. Oxford: Radcliffe Medical Press, 1999.
25. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005; 331: 263.
26. Chennavasin P, Brater DC. Nomograms for drug use in renal disease. Clin Pharmacokinet 1981; 6: 193-214.
27. Michael KA, Mohler JL, Blouin RA, Lucas BA, Rapp RP. Failure of creatinine clearance to predict gentamicin half-life in a renal transplant patient with diabetes mellitus. Clin Pharm 1985; 4: 572-575.
28. Maderazo EG, Sun H, Jay GT. Simplification of antibiotic dose adjustments in renal insufficiency: the DREM system. Lancet 1992; 340: 767-770.
29. Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003; 42: 217-228.
30. Kleinknecht D, Landais P, Goldfarb B. Analgesic and nonsteroidal anti-inflammatory drug-associated acute renal failure: a prospective collaborative study. Clin Nephrol 1986; 25: 275-281.
31. Shankel SW, Johnson DC, Clark PS, Shankel TL, O'Neil Jr WM. Acute renal failure and glomerulopathy caused by nonsteroidal anti-inflammatory drugs. Arch Intern Med 1992; 152: 986-990.
32. Minuz P, Barrow SE, Cockcroft JR, Ritter JM. Effects of nonsteroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension. Br J Clin Pharmacol 1990; 30: 519-526.
33. Weinstein S, Pfeffer M, Schor J, Indindoli L, Mintz M. Metabolites of naloxone in human urine. J Pharm Sci 1971; 60: 1567-1568.
34. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054.
35. Chen YF, Jobanputra P, Barton P et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12: 1-278, iii.
36. Rostom A, Moayyedi P, Hunt R. Canadian Consensus guidelines on long-term NSAID therapy and the need for gastroprotection. Aliment Pharmacol Ther 2009; 29: 481-496.
37. Boerner U. The metabolism of morphine and heroin in man. Drug Metab Rev 1975; 4: 39-73.
38. Barnes JN, Williams AJ, Tomson MJ, Toseland PA, Goodwin FJ. Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs. BMJ 1985; 290: 740-742.
39. Guay DR, Awni WM, Findlay JW et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988; 43: 63-71.
40. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31: 410-422.
41. Barnes JN, Goodwin FJ. Dihydrocodeine narcosis in renal failure. BMJ 1983; 286: 438-439.
42. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs 2001; 61: 955-977.
43. Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990; 67: 322-328.
44. Rischitelli DG, Karbowicz SH. Safety and efficacy of controlledrelease oxycodone: a systematic literature review. Pharmacotherapy 2002; 22: 898-904.
45. Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8: 13-18.
46. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33: 617-621.
47. Lee MA, Leng M, Cooper RM. Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis. Palliat Med 2005; 19: 259-260.
48. Foral PA, Ineck JR, Nystrom KK. Oxycodone accumulation in a hemodialysis patient. South Med J 2007; 100: 212-214.
49. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-285.
50. Raffa RB, Friderichs E, Reimann W et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993; 267: 331-340.
51. Desmeules JA. The tramadol option. Eur J Pain 2000; 4 (Suppl A): 15-21.
52. Scott LJ, Perry CM. Tramadol: a review of its use in perioperative pain. Drugs 2000; 60: 139-176.
53. Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996; 41: 7-12.
54. Sevcik J, Nieber K, Driessen B, Illes P. Effects of the central analgesic tramadol and its main metabolite, O-desmethyltramadol, on rat locus coeruleus neurones. Br J Pharmacol 1993; 110: 169-176.
55. Lintz W, Erlacin S, Frankus E, Uragg H. Metabolismus von tramadol bei mensch und tier (Biotransformation of tramadol in man and animal). Arzneimittelforschung 1981; 31: 1932-1943.
56. Gibson TP. Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Am J Med 1996; 101 (Suppl 1A): 47S-53S.
57. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet 1988; 1: 828.
58. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12-19.
59. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manage 1990; 5: S46-S62.
60. Portenoy RK, Khan E, Layman M et al. Chronic morphine therapy for pain for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology 1991; 41: 1457-1461.
61. Sawe J, Odar-Cederlof I. Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 1987; 32: 377-382.
62. Sear JW, Hand CW, Moore RA, McQuay HJ. Studies on morphine disposition: influence of renal failure on kinetics of morphine and its metabolites. Br J Anaesth 1989; 62: 28-32.
63. Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P. Morphine pharmacokinetics in renal failure. Anesthesiology 1987; 66: 327-331.
64. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. BMJ 1986; 292: 1548-1549.
65. Wolff J, Bigler D, Christensen CB, Rasmussen SN, Andersen HB, Tonnesen KH. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol 1988; 34: 353-357.
66. Hanna MH, D'Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 1993; 70: 511-514.
67. Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazar M, for the Canadian Palliative Care Clinical Trials Group. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. J Clin Oncol 1996; 14: 1713-1717.
68. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9: 84-96.
69. Davison SN, Mayo P. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3- glucuronide in hemodialysis patients. J Opioid Manage 2008; 4: 335, 339-336, 344.
70. Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001; 15: 26-34.
71. Morrison JD, Loan WB, Dundee JW. Controlled comparison of the efficacy of fourteen preparations in the relief of post-operative pain. BMJ 1971; 2: 287-290.
72. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer pain. Pain 1986; 25: 297-312.
73. Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology 1999; 13: 1275-1288.
74. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993; 52: 137-147.
75. Dole VP, Kreek MJ. Methadone plasma level: sustained by a reservoir of drug. Proc Natl Acad Sci USA 1973; 70: 10-15.
76. Pohland A, Boaz HE, Sullivan HR. Synthesis and identification of metabolites resulting from the biotransformation of D,Lmethadone in man and in the rat. J Med Chem 1971; 14: 194-197.
77. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980; 5: 197-205.
78. Furlan V, Hafi A, Dessalles MC, Bouchez J, Charpentier B, Taburet AM. Methadone is poorly removed by haemodialysis. Nephrol Dial Transplant 1999; 14: 254-255.
79. Miller JW, Anderson HH. The effect of N-demethylation on certain pharmacologic actions of morphine, codeine and meperidine in the mouse. J Pharmacol Exp Ther 1954; 112: 191-196.
80. Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, Reidenberg MM. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977; 86: 738-741.
81. Clotz MA, Nahata MC. Clinical uses of fentanyl, sufentanil, and alfentanil. Clin Pharm 1991; 10: 581-593.
82. Koren G, Crean PGGV, Klein J, MacLeod SM. Pharmacokinetics of fentanyl in children with renal disease. Res Commun Chem Pathol Pharmacol 1984; 46: 371-379.
83. McClain DA, Hug Jr CC. Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980; 28: 106-114.
84. Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17: 745-752.
85. Bower S. Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure. J Pharm Pharmacol 1982; 34: 102-106.
86. Mercadante S, Caligara M, Sapio M, Serretta R, Lodi F. Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage 1997; 13: 241-244.
87. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002; 46: 759-770.
88. McQuay H, Moore RA, Bullingham REE. Bubrenorphine kinetics. In: Foley KM, Inturrisi CE. (eds) Opioid Analgesics in the Management of Clinical Pain. New York: Raven, 1986; 271-278.
89. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197: 517-532.
90. Bullingham RE, McQuay HJ, Moore RA, Weir L. An oral buprenorphine and paracetamol combination compared with paracetamol alone: a single dose double-blind postoperative study. Br J Clin Pharmacol 1981; 12: 863-867.
91. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics 2003; 44: 515-520.
92. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64: 276-282.
93. Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine-and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272: 505-510.
94. Filitz J, Griessinger N, Sittl R, Likar R, Schuttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbupre norphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 2006; 10: 743-748.
95. Budd K, Chambers J, Dahan A, Dickenson T. Guidance about prescribing in palliative care. In: Twycross R, Wilcock A. (eds) Palliative Care Formulary 3. 2009 .
96. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2009; 323: 16-21.
97. Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005; 13: 97-103.
98. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Metaanalysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007; 23: 17-24.
99. Beal JE, Olson R, Lefkowitz L et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndromeassociated anorexia. J Pain Symptom Manage 1997; 14: 7-14.
100. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabisbased medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 50-52.
101. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-819.
102. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007; 29: 2068-2079.
103. Moore RA, Tramer MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998; 316: 333-338.
104. Zhang WY, Li Wan PA. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994; 46: 517-522.
105. Stein C, Machelska H, Schafer M. Peripheral analgesic and anti-inflammatory effects of opioids. Z Rheumatol 2001; 60: 416-424.
106. Twillman RK, Long TD, Cathers TA, Mueller DW. Treatment of painful skin ulcers with topical opioids. J Pain Symptom Manage 1999; 17: 288-292.